Literature DB >> 10602482

Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer.

S H Kang1, Y J Bang, Y H Im, H K Yang, D A Lee, H Y Lee, H S Lee, N K Kim, S J Kim.   

Abstract

The transforming growth factor-beta (TGF-beta) signaling pathway subserves an essential tumor suppressor function in various cell types. A heteromeric complex composed of TGF-beta type I (RI) and type II (RII) receptors is required for TGF-beta signaling. We have identified a subset of human gastric cancer cell lines which are insensitive to TGF-beta and which express a low level of TGF-beta type I receptor mRNA relative to a gastric cancer cell line which is highly responsive to TGF-beta. Using these cells, we show that hypermethylation of a CpG island in the 5' region of the TGF-beta RI gene provides another potentially important mechanism of escape from negative growth control by TGF-beta. This hypermethylation was found in four of five human gastric cancer cell lines and five out of 40 (12.5%) primary tumors examined. In human gastric cancer cell lines, treatment with the demethylating agent, 5-aza-2'-deoxycytidine, resulted in increased expression of the TGF-beta RI gene, but not the RII gene. Transient transfection of an RI expression vector into the TGF-beta resistant SNU-601 cell line restores TGF-beta responsiveness. These findings suggest that one of the mechanisms of escape from autocrine or paracrine growth control by TGF-beta during carcinogenesis could involve aberrant methylation of CpG islands in the 5' region of the TGF-beta RI gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10602482     DOI: 10.1038/sj.onc.1203146

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

1.  Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death.

Authors:  Sanjib Chowdhury; Gillian M Howell; Carol A Teggart; Aparajita Chowdhury; Jonathan J Person; Dawn M Bowers; Michael G Brattain
Journal:  J Biol Chem       Date:  2011-07-08       Impact factor: 5.157

2.  SMAD6 contributes to patient survival in non-small cell lung cancer and its knockdown reestablishes TGF-beta homeostasis in lung cancer cells.

Authors:  Hyo-Sung Jeon; Tatiana Dracheva; Sei-Hoon Yang; Daoud Meerzaman; Junya Fukuoka; Abbas Shakoori; Konstantin Shilo; William D Travis; Jin Jen
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

3.  Epigenetic regulation of beta2-adrenergic receptor expression in T(H)1 and T(H)2 cells.

Authors:  Jaclyn W McAlees; Laura T Smith; Robert S Erbe; David Jarjoura; Nicholas M Ponzio; Virginia M Sanders
Journal:  Brain Behav Immun       Date:  2010-11-01       Impact factor: 7.217

4.  Aberrant DNA methylation of integrin α4 in human breast cancer.

Authors:  Sung-Im Do; Eunkyung Ko; So Young Kang; Jeong Eon Lee; Seok Jin Nam; Eun Yoon Cho; Duk-Hwan Kim
Journal:  Tumour Biol       Date:  2014-04-24

5.  DNA methylation: old dog, new tricks?

Authors:  Cornelia G Spruijt; Michiel Vermeulen
Journal:  Nat Struct Mol Biol       Date:  2014-11       Impact factor: 15.369

Review 6.  TGFβ signaling in head and neck squamous cell carcinoma.

Authors:  R A White; S P Malkoski; X-J Wang
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

Review 7.  TGFBR1 and cancer susceptibility.

Authors:  Boris Pasche; Michael J Pennison; Hugo Jimenez; Minghui Wang
Journal:  Trans Am Clin Climatol Assoc       Date:  2014

Review 8.  Transforming growth factor beta (TGF-beta) and inflammation in cancer.

Authors:  Brian Bierie; Harold L Moses
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-16       Impact factor: 7.638

9.  Biology of SNU cell lines.

Authors:  Ja-Lok Ku; Jae-Gahb Park
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

10.  Aberrant methylation inactivates transforming growth factor Beta receptor I in head and neck squamous cell carcinoma.

Authors:  Teresita Muñoz-Antonia; Mariclara Torrellas-Ruiz; Jonathan Clavell; Linda A Mathews; Carlos A Muro-Cacho; Adriana Báez
Journal:  Int J Otolaryngol       Date:  2009-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.